Statements (16)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alternativeName |
N-methyl-4-(p-tolyl)-1,2,3,6-tetrahydropyridine-3-carboxamide
N-methyl-4-(4-methylphenyl)-1,2,3,6-tetrahydropyridine-3-carboxamide |
| gptkbp:chemicalFormula |
C14H18N2O
|
| gptkbp:clinicalTrialPhase |
Phase 2 (as of 2023)
|
| gptkbp:developedBy |
gptkb:Neumora_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
NMRA-511
|
| gptkbp:is_investigated_for |
treatment of depression
treatment of anxiety |
| gptkbp:mechanismOfAction |
5-HT1A receptor agonist
TAAR1 agonist |
| gptkbp:molecularWeight |
230.31 g/mol
|
| gptkbp:PubChem_CID |
132495
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:Neumora_Therapeutics
|
| gptkbp:bfsLayer |
7
|